Study details
Enrolling now
Mitoquinone/mitoquinol mesylate for preventing COVID-19
University of Texas Southwestern Medical Center
NCT IDNCT05886816ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
112
Study length
about 2.4 years
Ages
18–65
Locations
1 site in TX
What this study is about
This trial is testing whether mitoquinone/mitoquinol mesylate (Mito-MES) can prevent the development of COVID-19 in adults after exposure to someone with SARS-CoV-2. Participants will receive either Mito-MES or a placebo, and it will last for 882 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Mitoquinone/mitoquinol mesylate
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Duration of symptoms of SARS-CoV-2 infection, Severity of symptoms of SARS-CoV-2 infection
Body systems
Infectious